IN8bio announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors. Dr. Epperly will serve on IN8bio’s Compensation Committee as well as its Science & Technology Committee. She will work closely with the management team to provide guidance on strategic, operational, scientific, and clinical matters related to the Company’s pipeline of gamma-delta T cell therapies. Before joining IN8bio, Dr. Epperly most recently served as the COO of CARGO Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INAB:
- IN8bio Appoints Dr. Corinne Epperly to Board of Directors
- IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
- IN8bio presents data on patients treated with INB-200
- IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
- IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
